“…Several recent disclosures and results from two internal programs lead us to believe that racemic syntheses present viable manufacturing options even if DKR and CIDT are inaccessible by traditional means. When coupled with stereochemical editing, one can rapidly develop concise, asymmetric drug substance routes. This is important since drug development programs’ pace is ever accelerating …”